<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82067">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036970</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-C-1302</org_study_id>
    <nct_id>NCT02036970</nct_id>
  </id_info>
  <brief_title>Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT</brief_title>
  <official_title>A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
      patients with pulmonary hypertension to determine the recommended dose range, evaluate the
      change from baseline in 6-minute walk distance (6MWD) and determine the effect of
      Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease,
      interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO
      Group III or WHO Group V PH following 16 weeks of study participation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The molecular and pharmacological effects of bardoxolone methyl are broad through its
      induction of Nrf2 and suppression of NF-κB. Bardoxolone methyl may therefore address
      multiple facets of the pathophysiology of PH because it suppresses activation of
      proinflammatory mediators, enhances endothelial NO bioavailability, improves metabolic
      dysfunction, suppresses vascular proliferation, and prevents maladaptive remodeling.
      Furthermore, while existing therapies primarily target only smooth muscle cells, bardoxolone
      methyl targets multiple cell types relevant to PH, including endothelial cells, smooth
      muscle cells, and macrophages.

      This is a two-part study.

      Part 1: Part 1 of the study will include a dose-ranging phase and a dose-titration phase.

      Part 2 (extension period): All patients from Part 1 who complete the 16-week treatment
      period as planned will be eligible to continue directly into the extension period to
      evaluate the intermediate and long-term safety and efficacy of bardoxolone methyl.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 1] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 3] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Ranging Phase: Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 4] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Titration Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 3 weeks, escalating to [Dose 3] mg or placebo by mouth once daily at Week 4 for 13 weeks
If a patient experiences a dose-limiting toxicity, the investigator may de-escalate the dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <arm_group_label>Dose-Ranging Phase: Dose 1</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 2</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 3</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 4</arm_group_label>
    <arm_group_label>Dose-Titration Phase</arm_group_label>
    <other_name>RTA 402 capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose-Ranging Phase: Dose 1</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 2</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 3</arm_group_label>
    <arm_group_label>Dose-Ranging Phase: Dose 4</arm_group_label>
    <arm_group_label>Dose-Titration Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and female patients ≥ 18 to ≤ 75 years of age upon study consent;

          2. BMI &gt; 18.5 kg/m²

          3. Symptomatic pulmonary hypertension WHO class II and III;

          4. WHO Group I, III, or V PH according to the following criteria:

               1. If diagnosed with WHO Group I PAH, then on of the following subtypes:

                    -  Idiopathic or heritable PAH;

                    -  PAH associated with connective tissue disease;

                    -  PAH associated with simple, congenital systemic-to-pulmonary shunts at
                       least 1 year following shunt repair;

                    -  PAH associated with anorexigen or drug-induced toxicity;

                    -  PAH associated with human immunodeficiency virus (HIV); or

               2. If WHO Group III PH then primary diagnosis must be one of the following
                  subtypes:

                    -  Connective tissue disease associated ILD (CTD-ILD);

                    -  Idiopathic pulmonary fibrosis (IPF);

                    -  Nonspecific interstitial pneumonia (NSIP); or

               3. If WHO Group V PH then patient must be diagnosed with sarcoidosis;

          5. Had a diagnostic right heart catheterization performed and documented within 36
             months prior to Day 1 that confirmed a diagnosis of PH

          6. If WHO Group I, has been receiving no more than three (3) FDA-approved
             disease-specific PAH therapies except for intravenous (iv) prostacyclin/prostacyclin
             analogues. PAH therapy must be at a stable dose for at least 90 days prior to Day 1;

          7. Has adequate kidney function defined as an estimated glomerular filtration rate
             (eGFR) ≥ 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD)
             4-variable formula;

        Exclusion Criteria:

          1. Participation in other interventional clinical studies involving pharmaceutical
             products being tested or used in a way different from the approved form or when used
             for an unapproved indication within 30 days prior to Day 1;

          2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 3 months
             (90 days) prior to Day 1 or planned initiation during Part 1 of the study;

          3. Stopped receiving any PH chronic therapy within 60 days prior to Day 1;

          4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1;

          5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood
             pressure (BP) &gt; 160 mm Hg or sitting diastolic blood pressure &gt; 100 mm Hg during
             Screening after a period of rest;

          6. Has systolic BP &lt; 90 mm Hg during Screening after a period of rest;

          7. WHO Group III or V patients who at rest require supplemental oxygen at a rate of &gt;4
             L/min and have peripheral capillary oxygen saturation levels &lt;92%;

          8. Has a history of clinically significant left-sided heart disease and/or clinically
             significant cardiac disease,including but not limited to any of the following:

               1. Congenital or acquired valvular disease if clinically significant apart from
                  tricuspid valvular insufficiency due to pulmonary hypertension;

               2. Pericardial constriction;

               3. Restrictive or congestive cardiomyopathy;

               4. Left ventricular ejection fraction &lt; 40% per echocardiogram (ECHO) within 60
                  days of Day 1;

               5. Any current or prior history of symptomatic coronary disease (prior myocardial
                  infarction, percutaneous coronary intervention, coronary artery bypass graft
                  surgery, or anginal chest pain);

          9. Acutely decompensated heart failure within 30 days prior to Day 1, as per
             Investigator assessment;

         10. History of atrial septostomy within 180 days prior to Day 1;

         11. History of obstructive sleep apnea that is untreated;

         12. Has a history of portal hypertension or chronic liver disease, including hepatitis B
             and/or hepatitis C (with evidence of recent infection and/or active virus
             replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C);

         13. Serum aminotransferase (ALT or AST) levels &gt; the upper limit of normal (ULN) at
             Screening;

         14. For patients with HIV-associated PAH, any of the following:

               1. Concomitant active opportunistic infections within 180 days prior to Screening;

               2. Detectable viral load within 90 days prior to Screening;

               3. Cluster designation (CD+) T-cell count &lt; 200 mm3 within 90 days prior to
                  Screening;

               4. Changes in antiretroviral regimen within 90 days prior to Screening;

               5. Using inhaled pentamidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University Medical Center, Phoenix Advanced Lung Disease Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>602-839-6211</phone>
    </contact>
    <investigator>
      <last_name>Rajeev Saggar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>602-271-0832</phone>
    </contact>
    <investigator>
      <last_name>Jeremy Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>310-828-2878</phone>
    </contact>
    <investigator>
      <last_name>Victor Tapson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diagnamics Inc</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>760-310-0045</phone>
    </contact>
    <investigator>
      <last_name>Ramin Farsad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Healthcare System of Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>310-268-4314</phone>
    </contact>
    <investigator>
      <last_name>Shelley Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center - Division of Pulmonary and Critical Care</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>916-734-1554</phone>
    </contact>
    <investigator>
      <last_name>Roblee Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>415-514-1125</phone>
    </contact>
    <investigator>
      <last_name>Teresa Demarco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine - Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>650-725-9861</phone>
    </contact>
    <investigator>
      <last_name>Roham Zamanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>310-222-3560</phone>
    </contact>
    <investigator>
      <last_name>Ronald J. Oudiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver - Division of Pulmonary Sciences</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>720-848-6552</phone>
    </contact>
    <investigator>
      <last_name>David Badesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Marjorie George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, P.C</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>303-703-2124</phone>
    </contact>
    <investigator>
      <last_name>Ira Dauber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center - Department of Rheumatology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>202-444-2000</phone>
    </contact>
    <investigator>
      <last_name>Virginia Steen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tunay Kuru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic of Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>954-627-2820</phone>
    </contact>
    <investigator>
      <last_name>Franck Rahaghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care of Atlanta - Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>404-236-8113</phone>
    </contact>
    <investigator>
      <last_name>Paul Boyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>773-702-5589</phone>
    </contact>
    <investigator>
      <last_name>Mardi Gomberg-Maitland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>502-587-8000</phone>
    </contact>
    <investigator>
      <last_name>John McConnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center - Heart and Vascular Clinical Trials &amp; Research Division</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>504-842-6729</phone>
    </contact>
    <investigator>
      <last_name>Stacy Mandras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center - Division of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>207-662-6550</phone>
    </contact>
    <investigator>
      <last_name>Joel Wirth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chest Medicine Associates</name>
      <address>
        <city>South Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>207-828-1122</phone>
    </contact>
    <investigator>
      <last_name>Joel Wirth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>617-636-1334</phone>
    </contact>
    <investigator>
      <last_name>Nicholas Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>305-613-9411</phone>
    </contact>
    <investigator>
      <last_name>Aaron Waxman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>617-638-4475</phone>
    </contact>
    <investigator>
      <last_name>Harrison W. Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>314-747-8174</phone>
    </contact>
    <investigator>
      <last_name>Murali Chakinala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Lana Melendres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>516-663-9582</phone>
    </contact>
    <investigator>
      <last_name>Shilpa DeSouza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai, Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>201-230-5689</phone>
    </contact>
    <investigator>
      <last_name>Roxana Sulica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>212-746-2698</phone>
    </contact>
    <investigator>
      <last_name>Evelyn Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester - University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>585-486-0869</phone>
    </contact>
    <investigator>
      <last_name>Jim White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>513-585-1707</phone>
    </contact>
    <investigator>
      <last_name>Peter Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care &amp; Sleep Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>513-558-3257</phone>
    </contact>
    <investigator>
      <last_name>Jean Elwing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>614-366-2258</phone>
    </contact>
    <investigator>
      <last_name>Namita Sood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>405-608-1281</phone>
    </contact>
    <investigator>
      <last_name>John Kingrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>717-544-1777</phone>
    </contact>
    <investigator>
      <last_name>Justin Roberts, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>412-648-7040</phone>
    </contact>
    <investigator>
      <last_name>Robyn Domsic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>214-645-6493</phone>
    </contact>
    <investigator>
      <last_name>Fernando Torres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonja Bartolome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BreatheAmerica El Paso, Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>915-225-4917</phone>
    </contact>
    <investigator>
      <last_name>Hernando Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>713-363-7537</phone>
    </contact>
    <investigator>
      <last_name>Adanni Frost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas - Health Science Center &amp; Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>713-500-6851</phone>
    </contact>
    <investigator>
      <last_name>Bela Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>713-500-7118</phone>
    </contact>
    <investigator>
      <last_name>Maureen Mayes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>801-507-4606</phone>
    </contact>
    <investigator>
      <last_name>Lynn Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>801-585-2944</phone>
    </contact>
    <investigator>
      <last_name>John Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Iyer Clinic</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20171</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>703-579-6885</phone>
    </contact>
    <investigator>
      <last_name>Ravi Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>414-649-5097</phone>
    </contact>
    <investigator>
      <last_name>Dianne Zwicke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>Bardoxolone methyl</keyword>
  <keyword>6-minute walk distance</keyword>
  <keyword>CDDO-me</keyword>
  <keyword>RTA 402</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
